Jean Jacques Bienaime bought $493K of Ascendis Pharma A/S (ASND)
Executed Aug 14, disclosed Aug 19, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 18), the stock returned +0.5% (delay-adjusted); from the execution session (Aug 14), +8.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Jean Jacques Bienaime (Director) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 1 sale), most often in Immunome, Inc. (IMNM). Across 3 priced purchase filings, the average 21-session return was +5.7% from execution and +7.2% from disclosure (delay-adjusted; derived). The largest single filing was $493K of ASND (2,000 sh across 2 lots, as filed), executed Aug 14.
Healthcare · Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→